JOURNAL OF PHARMA INSIGHTS AND RESEARCH ISSN NO. 3048-5428

REVIEW ARTICLE

Molecular Mechanisms for Neural Restoration and the Role of Gene Therapy for the Treatment of Paralysis

Sravani Devi Kakara*[1], Sai Sri Mounika Tanapathi[2], Gangothri Siva Sai Bhavani Tangella[2], Mercy Tadepalli[2], Anubalu Sirra[2], Lakshmi Durgambika Tammana[2]

[1] *Associate Professor, Department of Pharmaceutical Analysis, VJs College of Pharmacy, Diwancheruvu, Rajahmundry, Andhra Pradesh, India*
[2] *UG Scholar, Department of Pharmaceutical Analysis, VJs College of Pharmacy, Diwancheruvu, Rajahmundry, Andhra Pradesh, India*

Publication history: Received on 30th November 2025; Revised on 11th January 2026; Accepted on 15th January 2026

Article DOI: 10.69613/7cms3c25

Abstract: Paralysis is one of the most debilitating neurological conditions, which can occur due to traumatic injury or degenerative processes within the central nervous system. Earlier the treatment was limited to symptomatic management and physical rehabilitation, which failed to address the underlying cellular destruction. The research on molecular regeneration through gene therapy indicates a shift toward curative interventions. This review provides the current knowledge regarding the genetic modulation of damaged neural circuits to promote axonal regrowth and functional recovery. The regenerative capacity of the adult central nervous system is severely limited by a complex inhibitory environment and the intrinsic loss of growth potential in mature neurons. Genetic interventions aim to overcome these barriers by delivering neurotrophic factors, silencing growth-inhibitory pathways, and utilizing precise genome editing tools like CRISPR-Cas9. Viral vector systems, particularly adeno-associated viruses, have demonstrated high efficacy in delivering therapeutic transgenes to specific neuronal populations. Preclinical models indicate that modulating the PTEN/mTOR pathway and enhancing the expression of brain-derived neurotrophic factor can trigger significant axonal sprouting and synaptic reconnection. The integration of molecular biology with neural engineering offers a plausible path toward reversing permanent paralysis while clinical translation faces hurdles regarding delivery across the blood-brain barrier and the management of host immune responses. This review shows the transition from palliative care to a molecular-driven paradigm of neural repair.

Keywords: Axonal Regeneration; Spinal Cord Injury; Viral Vectors; CRISPR-Cas9; Neurotrophic Factors.

1. Introduction

Paralysis describes the functional loss of voluntary muscle control and sensory perception, typically resulting from structural damage to the brain or spinal cord. The global burden of this condition is substantial, with millions of individuals suffering from spinal cord injuries (SCI), ischemic strokes, or motor neuron diseases such as Amyotrophic Lateral Sclerosis (ALS) [1]. In the central nervous system (CNS), the failure of spontaneous regeneration after an insult is the primary cause of permanent disability. Unlike the peripheral nervous system, which retains a degree of plasticity, the adult CNS is characterized by a hostile extracellular environment and an intrinsic genetic program that favors stability over growth [2].

Current clinical standards, including neurosurgery for decompression, high-dose corticosteroid administration, and intensive neurorehabilitation, primarily focus on preserving remaining tissue and optimizing existing function [3]. These interventions do not stimulate the de novo growth of axons or the replacement of lost motor neurons.

Consequently, the development of molecular therapies that can re-initiate the developmental growth programs of neurons has become a critical objective in regenerative medicine. Gene therapy offers a unique mechanism for long-term therapeutic protein expression within the CNS, bypassing the pharmacokinetic limitations of traditional systemic drug delivery [4]. Recent advances in viral vector engineering and precise genome editing have expanded the toolkit available for neural repair.

Researchers can modify the cellular response to injury by introducing specific genetic sequences into damaged cells, attenuate the formation of glial scars, and provide a continuous supply of growth-promoting factors directly to the lesion site [5]. This review provides a detailed analysis of the molecular mechanisms underlying paralysis and the genetic strategies designed to achieve functional restoration.

* Corresponding author: Sravani Devi Kakara

2. Pathophysiology of Paralysis and Neural Failure

The transition from acute injury to chronic paralysis involves a multifaceted cascade of mechanical, chemical, and cellular events. To design effective genetic interventions, a deep comprehension of the barriers to regeneration within the CNS is required.

2.1. Primary and Secondary Degenerative Cascades

The initial mechanical trauma to the spinal cord or the ischemic event in the brain constitutes the primary injury, leading to the immediate necrosis of neurons and glial cells. This phase is followed by a prolonged secondary injury cascade that expands the area of damage beyond the original site [6].

2.1.1. Excitotoxicity and Oxidative Stress

Following the rupture of cellular membranes, there is a massive release of excitatory neurotransmitters, primarily glutamate. This excess glutamate overactivates ionotropic receptors, leading to a lethal influx of calcium ions into the neurons a process known as excitotoxicity [7]. This ion imbalance triggers mitochondrial dysfunction and the production of reactive oxygen species (ROS), which further damage DNA and lipid membranes, causing the apoptosis of spared neurons in the penumbra region.

2.1.2. The Inflammatory Response

The disruption of the blood-brain barrier facilitates the infiltration of peripheral immune cells, including neutrophils and macrophages, into the CNS. While the inflammatory response is necessary for clearing debris, the chronic activation of microglia and the release of pro-inflammatory cytokines such as TNF-alpha and IL-1beta create a neurotoxic environment that inhibits endogenous repair mechanisms [8].

2.2. The Glial Scar

One of the most significant impediments to neural regeneration is the formation of the glial scar. While the scar serves an early protective function by sequestering the injury site and preventing the spread of inflammation, its persistence creates a permanent physical and biochemical barrier [9].



Figure 1. The Pathophysiological Axis of Central Nervous System Regenerative Failure

Reactive astrocytes are the primary components of the glial scar. Upon activation, they proliferate and undergo hypertrophy, forming a dense meshwork around the lesion. These astrocytes secrete Chondroitin Sulfate Proteoglycans (CSPGs), which are highly inhibitory to axonal extension [10]. CSPGs interact with specific receptors on the growth cones of axons, such as Protein Tyrosine Phosphatase Sigma (PTP-sigma), triggering growth cone collapse and preventing the re-entry of axons into the damaged area.

2.3. Intrinsic Loss of Regenerative Potential

Apart from environmental inhibitors, mature CNS neurons lose the intrinsic ability to grow axons as they age. This is regulated by developmental shifts in gene expression.

During development, neurons express high levels of growth-associated proteins like GAP-43 and members of the Krüppel-like factor (KLF) family. As the CNS matures, the expression of growth-promoting KLFs is downregulated, while growth-inhibitory KLFs are upregulated [11]. The activation of the Phosphatase and Tensin Homolog (PTEN) pathway acts as a major brake on the mammalian target of rapamycin (mTOR) signaling, which is essential for protein synthesis and axonal elongation [12]. The suppression of these pathways ensures the stability of adult neural circuits but prevents recovery following injury.

3. Principles of Gene Delivery and Vector Engineering in the CNS

The therapeutic efficacy of genetic intervention for paralysis is heavily dependent on the precision and efficiency of the delivery system. Targeting the central nervous system (CNS) presents unique anatomical challenges, necessitating the use of specialized vectors that can navigate the blood-brain barrier and achieve stable transgene expression in post-mitotic neurons [13].

3.1. Viral Vector Systems for Neural Transduction

Viruses have evolved sophisticated mechanisms to bypass cellular defenses and deliver genetic material into the host nucleus. By replacing viral pathogenic genes with therapeutic sequences, researchers utilize these biological machines for site-specific repair.

3.1.1. Adeno-Associated Viruses (AAV)

Adeno-associated viruses are currently the gold standard for CNS gene therapy due to their low immunogenicity and ability to provide long-term gene expression without integrating into the host genome [14]. Different AAV serotypes exhibit distinct tropisms; for instance, AAV9 and AAV-rh10 have demonstrated the capability to cross the blood-brain barrier following systemic administration, allowing for non-invasive targeting of motor neurons in the spinal cord [15]. Engineering the AAV capsid further enhances targeting precision, reducing off-target effects in peripheral organs like the liver.

Table 1. Comparison of Viral and Non-Viral Delivery Systems.

Delivery Vehicle	Vector Type	Packaging Capacity	Duration of Expression	Immunogenicity	Primary CNS Application
AAV	Viral	~4.7 kb	Long-term (Episomal)	Low	Targeted motor neuron transduction (e.g., AAV9)
Lentivirus	Viral	~ 8-10 kb	Permanent (Integrated)	Moderate	Stable expression in dividing neural stem cells
Adenovirus	Viral	~ 30 kb	Transient	High	Acute neuroprotection following immediate trauma
LNP	Non-Viral	Unlimited	Transient (mRNA)	Minimal	Localized delivery of growth factors or CRISPR components
Gold Nanoparticles	Non-Viral	High Surface Area	Transient	Very Low	Precision delivery via optoporation or thermal release

3.1.2. Lentiviral and Adenoviral Platforms

Lentiviral vectors, derived from HIV-1, offer a larger packaging capacity than AAVs, making them suitable for delivering complex genetic circuits or large trophic factor genes [16]. Unlike AAVs, lentiviruses integrate into the host genome, which ensures that the therapeutic effect is passed to daughter cells a feature particularly relevant when combined with stem cell-based therapies. Adenoviral vectors, while highly efficient at transduction, often trigger a robust inflammatory response, which limits their utility to acute, short-term applications where high-level protein expression is required immediately following trauma [17].

3.2. Non-Viral Delivery and Nanotechnology

Inorder to circumvent the limitations of viral vectors, including restricted payload size and potential immunogenicity, non-viral alternatives are under active development. Lipid nanoparticles (LNPs) and polymer-based carriers provide a versatile platform for delivering messenger RNA (mRNA) or plasmid DNA [18]. These systems can be functionalized with ligands that target specific neuronal receptors, such as the transferrin receptor, to facilitate transcytosis across the blood-brain barrier. The use of gold nanoparticles and carbon nanotubes is being investigated for their ability to provide localized delivery through electroporation or laser-induced transfection [19].

4. Molecular Strategies for Overcoming Intrinsic Inhibitors

Restoring motor function requires the reactivation of dormant growth programs within mature neurons. Genetic strategies often focus on "releasing the brakes" that naturally prevent axonal elongation in the adult CNS.

4.1. Modulation of the PTEN/mTOR Pathway

The Phosphatase and Tensin Homolog (PTEN) is a critical negative regulator of the mammalian target of rapamycin (mTOR) pathway. In adult neurons, high PTEN activity suppresses protein synthesis and prevents the formation of growth cones [20].

4.1.1. Genetic Silencing of PTEN

Experimental deletion of the PTEN gene using shRNA or CRISPR-Cas9 has yielded some of the most robust examples of axonal regeneration in preclinical models of spinal cord injury. By silencing PTEN, neurons regain the ability to synthesize the proteins necessary for cytoskeletal assembly and mitochondrial transport, leading to extensive long-distance regrowth of corticospinal tract axons [21]. However, the permanent suppression of PTEN carries a theoretical risk of oncogenic transformation, necessitating the development of inducible systems that can turn the regenerative program off once reconnection is achieved.

4.1.2. SOCS3 and KLF Family Regulation

Other intrinsic inhibitors include the Suppressor of Cytokine Signaling 3 (SOCS3) and specific Krüppel-like factors (KLFs). SOCS3 inhibits the JAK/STAT pathway, which is essential for the regenerative response to injury [22]. Concurrent deletion of SOCS3 and PTEN has been shown to act synergistically, promoting even greater axonal sprouting than either intervention alone. Similarly, modulating the balance of KLFs upregulating growth-promoting members like KLF7 while silencing inhibitory ones like KLF4 represents a promising avenue for inducing a pro-regenerative state in damaged motor neurons [23].

4.2. Environmental Modification and Scar Degradation

Apart from intrinsic factors, gene therapy can be used to modify the extracellular matrix to make it more permissive to growth. The delivery of genes encoding enzymes such as Chondroitinase ABC via viral vectors allows for the localized digestion of the inhibitory CSPGs within the glial scar [24]. This enzymatic "clearing" of the path enables regrowing axons to traverse the lesion site. When combined with the delivery of neurotrophic factors, this approach addresses both the lack of growth drive and the physical barriers presented by the injury environment.

Table 2. Intrinsic Growth Inhibitors and Genetic Counter-Measures

Inhibitor Class	Molecular Target	Mechanism of Inhibition	Genetic Intervention Strategy
Intracellular	PTEN	Suppresses mTOR-mediated protein synthesis	CRISPR/shRNA-mediated gene silencing
Intracellular	SOCS3	Blocks JAK/STAT regenerative signaling	Viral-mediated deletion (AAV-Cre/LoxP)
Extracellular	CSPGs	Causes growth cone collapse via PTPσ	Genetic delivery of Chondroitinase ABC
Myelin-Derived	Nogo-A	Signals through NgR1 to inhibit elongation	RNAi or antibody-encoding transgene delivery
Transcriptional	KLF4	Represses pro-regenerative gene suites	Upregulation of KLF7 via CRISPRa

5. Neurotrophic Factor Augmentation and Synaptic Stabilization

Neurotrophic factors are endogenous signaling proteins that regulate the survival, development, and function of neurons. In the context of paralysis, the localized and sustained delivery of these factors via gene therapy provides a powerful stimulus for both protecting spared neurons and encouraging the growth of new connections [25].

5.1. Brain-Derived Neurotrophic Factor (BDNF) and NT-3

BDNF and Neurotrophin-3 (NT-3) are critical for the maintenance of the corticospinal tract and sensory pathways. Genetic upregulation of BDNF at the injury site has been shown to prevent the atrophy of motor neurons and stimulate axonal sprouting [26]. Interestingly, BDNF also plays a role in synaptic plasticity, helping regrowing axons to form functional synapses with target interneurons, which is essential for translating anatomical regrowth into motor control. NT-3 delivery, often targeted to the distal segments of a spinal lesion, acts as a chemoattractant, guiding regrowing axons across the "gap" created by the injury [27].

5.2. Glial Cell Line-Derived Neurotrophic Factor (GDNF)

GDNF is particularly effective in protecting alpha-motor neurons, which are responsible for direct muscle innervation. Following peripheral nerve damage or spinal cord trauma, the loss of GDNF signaling leads to rapid neuronal apoptosis. Gene therapy utilizing AAV-GDNF ensures a stable supply of this factor, significantly improving hind-limb grip strength and coordination in chronic injury models [28]. However, the dosage of GDNF must be strictly regulated; excessive concentrations can lead to "trapping" of axons, where they bundle around the source of the factor instead of continuing toward their distal targets.

Table 3. Functional Roles of Neurotrophic Factors in Spinal Cord and Brain Repair

Factor	Primary Target Cells	Molecular Mechanism	Effect on Neural Circuitry
BDNF	Corticospinal neurons	TrkB receptor activation	Stimulates axonal sprouting and synaptic plasticity
NT-3	Sensory and motor axons	TrkC signaling	Acts as a chemoattractant for long-distance guidance
GDNF	Alpha-motor neurons	Ret/GFRα1 complex	Prevents motor neuron apoptosis and improves grip strength
NGF	Cholinergic neurons	TrkA/p75NTR binding	Supports survival of basal forebrain neurons post-stroke
CNTF	Retinal ganglion cells	JAK/STAT pathway	Enhances survival of injured optic nerve fibers

6. Precision Genome Editing with CRISPR-Cas9

The advent of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and its associated protein Cas9 has revolutionized the ability to perform site-specific genomic modifications. Unlike traditional gene addition, CRISPR allows for the precise "knockout" of inhibitory genes or the "knock-in" of repair templates [29].

6.1. Targeted Disruption of Inhibitory Pathways

Genes like PTEN and SOCS3 act as molecular brakes on regeneration. CRISPR-Cas9 provides a more permanent and targeted method for silencing these genes compared to RNA interference (RNAi) [30]. CRISPR can be used to modify the regulatory elements of genes, such as enhancers, to re-activate embryonic growth programs in adult neurons without permanently altering the protein-coding sequence.

6.2. Epigenetic Modulation (CRISPRa/i)

Apart from cutting DNA, catalytically inactive Cas9 (dCas9) can be fused to transcriptional activators (CRISPRa) or repressors (CRISPRi). This allows for the precise tuning of gene expression levels rather than a complete binary on/off switch [31]. For example, CRISPRa can be used to simultaneously upregulate a suite of regeneration-associated genes (RAGs), mimicking the complex natural response observed in the peripheral nervous system. This multiplexing capability is a significant advantage over viral delivery of single cDNA sequences.



Figure 2. Comparison of Precise Neural Genomic Modulation

7. Stem Cell-Assisted Gene Therapy

Combining cellular replacement with genetic modification offers a dual-action approach to neural repair. Stem cells serve as both a biological scaffold to bridge the lesion and a vehicle for the sustained delivery of therapeutic proteins [32].

7.1. Engineering the Graft Environment

Neural Stem Cells (NSCs) can be genetically modified ex vivo to overexpress growth factors before they are transplanted into the injury site. These "designer grafts" not only differentiate into new neurons and glia to replace lost tissue but also secrete a continuous supply of BDNF or GDNF to support the survival of the host's endogenous axons [33]. Recent studies have demonstrated that reducing the dosage of certain genes like SOX9 within these grafts can mitigate glial scar formation within the transplant, allowing for better integration with the host spinal cord [34].

7.2. Bridging the Lesion Gap

In complete spinal cord transections, the physical gap prevents any form of signaling. Engineered stem cell grafts provided with guidance cues either through genetic expression of cell adhesion molecules or localized neurotrophin gradients have shown the ability to guide axons across these distances, forming "relay" circuits that bypass the site of damage [35]. This structural healing is a prerequisite for the restoration of voluntary movement in severe paralysis.



Figure 3. Gene Therapy Intervention in Paralysis

8. Constraints of Gene Therapy

While the molecular potential of gene therapy is vast, several substantial hurdles impede its transition from laboratory models to standard clinical practice. These challenges are categorized into delivery mechanics, biological safety, and functional integration [36].

8.1. Delivery Barriers and the Blood-Brain Barrier (BBB)

The BBB remains the most significant anatomical obstacle to non-invasive gene delivery. Although specific AAV serotypes like AAV9 can cross the BBB, the efficiency is often too low to achieve therapeutic concentrations throughout the entire spinal cord or

brain without using excessively high viral titers. High systemic doses increase the risk of hepatotoxicity and trigger robust immune responses against the viral capsid [37]. Direct intraparenchymal injections, while bypass the BBB, are inherently invasive and carry the risk of mechanical damage to already fragile neural tissue.

8.2. Immunogenicity and Host Response

The human immune system frequently recognizes viral vectors as foreign pathogens. Many individuals possess pre-existing neutralizing antibodies against common AAV serotypes due to prior natural exposure, which can completely neutralize the therapeutic vector before it reaches its target neurons [38]. The long-term expression of a non-human protein or even an overexpressed endogenous protein may trigger a T-cell-mediated immune response, leading to the destruction of the very neurons the therapy intends to save.

Table 4. Clinical and Technical Barriers to Translation

Barrier Type	Specific Challenge	Impact on Treatment Efficacy	Potential Mitigation Strategy
Biological	Blood-Brain Barrier	Restricted access for systemic vectors	Capsid engineering and focused ultrasound
Immunological	Neutralizing Antibodies	Vector neutralization before target entry	Plasmapheresis or decoy capsid administration
Safety	Off-Target Editing	Mutations in non-target genomic loci	High-fidelity Cas9 variants and RNP delivery
Functional	Circuit Miswiring	Formation of non-functional synapses	Combined physical rehabilitation and optogenetics
Logistical	Manufacturing Costs	High price of GMP-grade viral production	Development of stable producer cell lines

8.3. Off-Target Effects and Oncogenic Risks

Precision remains a concern, particularly with genome editing tools like CRISPR-Cas9. Unintended DNA cleavages (off-target effects) could potentially disrupt tumor suppressor genes or activate oncogenes, leading to malignancy [39]. Moreover, the permanent silencing of growth inhibitors like PTEN must be handled with extreme caution, as the PTEN/mTOR pathway is a central regulator of cell growth; chronic overactivation of this pathway is a hallmark of several cancers.

9. Future Scope

The next generation of gene therapy for paralysis is moving toward smarter, more controllable systems that integrate with other medical technologies.

9.1. Inducible Gene Switches and Circuits

To address the safety concerns of permanent transgene expression, researchers are developing "gene switches" that allow clinicians to turn therapeutic protein production on or off using small-molecule drugs like tetracycline or through light-activated optogenetic systems [40]. This capability is crucial for growth factor delivery, where an initial "burst" of protein may be needed to stimulate regeneration, followed by a lower maintenance dose to stabilize new synapses.

9.2. Personalized Genomic Medicine

Therapies will increasingly be tailored to the individual's specific injury profile. Advances in single-cell RNA sequencing allow for the identification of the exact sub-populations of neurons that have failed to regenerate, enabling the design of viral vectors with promoters that target only those specific cells [41].

9.3. Integration with Neuroprosthetics and AI

The future of paralysis treatment likely lies in "hybrid" therapies. Gene therapy can be used to biologically repair the "hardware" of the nervous system (the axons and neurons), while neuroprosthetic devices and brain-computer interfaces (BCIs) provide the "software" to control them [42]. Artificial intelligence can assist in analyzing motor patterns to optimize the timing of gene expression during rehabilitation, ensuring that new connections are reinforced through functional use.

Table 5. Comparison of Traditional Clinical Management vs. Gene Therapy

Parameter	Traditional Neurorehabilitation	Molecular Gene Therapy
Primary Goal	Optimization of spared function	Biological repair of damaged circuits
Mechanism	Compensation and physical exercise	De novo axonal growth and synaptic repair
Timeframe	Lifelong management required	Potential for "one-time" curative intervention
Targeting	Behavioral/Systemic	Cellular/Genetic
Regenerative Potential	Negligible (Incapable of axonal growth)	Significant (Triggers developmental growth programs)

10. Conclusion

Gene therapy has transitioned from a speculative concept to a rigorous molecular strategy for reversing the permanent deficits associated with paralysis. These interventions offer a path toward true biological recovery by addressing both the intrinsic genetic limitations of mature neurons and the hostile environment of the injured central nervous system. The synergy of viral vector engineering, CRISPR-based precision editing, and neurotrophic factor modulation has demonstrated remarkable success in restoring axonal continuity and motor function in preclinical models. While significant challenges regarding delivery efficiency and long-term safety persist, the rapid pace of innovation in molecular medicine suggests that genetic restoration of neural circuits is an attainable clinical goal. As multi-modal therapies continue to evolve, the prospect of transforming paralysis from a permanent disability into a treatable condition becomes increasingly plausible.

References

[1] Cunningham CJ, Viskontas M, Janowicz K, et al. The potential of gene therapies for spinal cord injury repair: a systematic review and meta-analysis of pre-clinical studies. Neural Regen Res. 2022;17(11):2335-2342.

[2] Zeng CW, Zhang CL. Neuronal regeneration after injury: a new perspective on gene therapy. Front Neurosci. 2023;17:1181659.

[3] Talifu Z, Zhang C, Xu X, et al. Neuronal repair after spinal cord injury by in vivo astrocyte reprogramming mediated by overexpression of NeuroD1 and Neurogenin-2. Biol Res. 2024;57(1):15.

[4] Liu JA, et al. Transplanting human neural stem cells with ~50% reduction of SOX9 gene dosage promotes tissue repair and functional recovery from severe spinal cord injury. Adv Sci. 2023;10(14):2206124.

[5] Gál I, et al. mRNA-LNP non-viral delivery platform for neurotrophic or anti-inflammatory factors to promote neuronal regeneration after SCI. Neural Regen Res. 2024;19(1):122-129.

[6] Petrov P, et al. Advances of Genome Editing with CRISPR/Cas9 in Neurodegeneration: The Right Path towards Therapy. Biomedicines. 2023;11(3):809.

[7] Gao Y, et al. Gene transfer of GDNF promotes functional recovery after spinal cord contusion. J Neurosci Res. 2003;72(2):153-160.

[8] Zhang F, et al. Intranasal Delivery of BDNF-loaded Small Extracellular Vesicles for Treating Acute Spinal Cord Injury in Rats & Monkeys. Neurotherapeutics. 2023;20:1115-1130.

[9] Qi S, Han M. CRISPR-TO: Technology to deliver RNA to specific parts of neurons, helping regrowth. Stanford News. 2025 Jan 15.

[10] Silver J, Miller JH. Regeneration beyond the glial scar. Nat Rev Neurosci. 2004;5(2):146-156.

[11] Moore DL, et al. KLF family members regulate intrinsic axon regeneration ability. Science. 2009;326(5950):298-301.

[12] Park KK, et al. Promoting axon regeneration in the adult CNS by PTEN deletion. Science. 2008;322(5903):963-966.

[13] O'Shea TM, et al. Genetic strategies for central nervous system repair. Neuron. 2017;94(4):725-745.

[14] Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019;18(5):358-378.

[15] Foust KD, et al. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol. 2009;27(1):59-65.

[16] Blömer U, et al. Highly efficient gene transfer into adult neurons with lentivirus vectors. J Virol. 1997;71(9):6641-6649.

[17] Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet. 2003;4(5):346-358.

[18] Kulkarni JA, et al. Lipid Nanoparticles Enabling Gene Therapies. Nucleic Acid Ther. 2018;28(3):146-157.

[19] Paviolo C, et al. Nanoparticles for gene delivery to the central nervous system. Front Neurosci. 2017;11:303.

[20] Liu K, et al. PTEN deletion enhances the regenerative ability of adult corticospinal neurons. Nat Neurosci. 2010;13(9):1075-1081.

[21] Sun F, et al. Sustained axon regeneration by PTEN deletion and mTOR activation. Nature. 2011;480(7377):371-375.

[22] Smith PD, et al. SOCS3 deletion promotes optic nerve regeneration in vivo. Neuron. 2009;64(5):617-623.

[23] Blackmore MG, et al. KLF7 engineered to be a potent activator of axon growth. Mol Cell Neurosci. 2012;50(3-4):273-282.

[24] Bradbury EJ, et al. Chondroitinase ABC promotes functional recovery after spinal cord injury. Nature. 2002;416(6881):636-640.

[25] Tuszynski MH, Steward O. Concepts and methods for the study of axonal regeneration in the CNS. Neuron. 2012;76(6):1079-1099.

[26] Lu P, et al. BDNF-expressing grafts promote spinal cord repair. Sci Transl Med. 2012;4(158):158ra145.

[27] Grill R, et al. Cellular delivery of neurotrophin-3 promotes corticospinal axonal growth and partial functional recovery after spinal cord injury. J Neurosci. 1997;17(14):5560-5572.

[28] Blesch A, Tuszynski MH. GDNF-expressing grafts promote restoration of function after spinal cord injury. J Comp Neurol. 2003;467(3):403-417.

[29] Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346(6213):1258096.

[30] He Z, Jin Y. Intrinsic Control of Axon Regeneration. Neuron. 2016;90(3):437-451.

[31] Gilbert LA, et al. Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation. Cell. 2014;159(3):647-661.

[32] Assunção-Silva RC, et al. Hydrogels and Cell Based Therapies in Spinal Cord Injury. Stem Cells Int. 2015;2015:948040.

[33] Rosenzweig ES, et al. Restorative effects of human neural stem cell grafts in primates. Nat Med. 2018;24(4):484-490.

[34] McKillop WM, et al. Reducing SOX9 Expression Promotes Axonal Growth and Functional Recovery After Spinal Cord Injury. PLoS One. 2016;11(8):e0161166.

[35] Alto LT, et al. Chemotropic guidance facilitates axonal regeneration and synapse formation after spinal cord injury. Nat Neurosci. 2009;12(9):1106-1113.

[36] Ginn SL, et al. Gene therapy clinical trials worldwide to 2017: An update. J Gene Med. 2018;20(5):e3015.

[37] Mingozzi F, High KA. Immune responses to AAV vectors: overcoming barriers to clinical success. Nat Rev Microbiol. 2013;11(7):459-470.

[38] Colella P, Ronzitti G, Mingozzi F. Emerging Issues in AAV-Mediated In Vivo Gene Therapy. Mol Ther Methods Clin Dev. 2018;8:87-104.

[39] Fu Y, et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol. 2013;31(9):822-826.

[40] Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci U S A. 1992;89(12):5547-5551.

[41] Macosko EZ, et al. Highly Parallel Genome-wide Expression Profiling of Individual Cells using Droplet Barcoding. Cell. 2015;161(5):1202-1214.

[42] Donoghue JP. Connecting cortex to machines: recent advances in brain interfaces. Nat Neurosci. 2002;5 Suppl:1085-1088.